Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts.

Wellenius GA, Mukamal KJ, Kulshreshtha A, Asonganyi S, Mittleman MA.

Circulation. 2008 May 6;117(18):2313-9. doi: 10.1161/CIRCULATIONAHA.107.741058. Epub 2008 Apr 21.

PMID:
18427130
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Self-reported anxiety and the risk of clinical events and atherosclerotic progression among patients with Coronary Artery Bypass Grafts (CABG).

Rosenbloom JI, Wellenius GA, Mukamal KJ, Mittleman MA.

Am Heart J. 2009 Nov;158(5):867-73. doi: 10.1016/j.ahj.2009.08.019. Epub 2009 Sep 24.

PMID:
19853710
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL.

J Am Coll Cardiol. 2000 Nov 15;36(6):1877-83.

PMID:
11092659
[PubMed - indexed for MEDLINE]
Free Article
4.

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.

White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators.

Circulation. 2001 Nov 27;104(22):2660-5.

PMID:
11723015
[PubMed - indexed for MEDLINE]
Free Article
5.

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY trial investigators.

Can J Cardiol. 2009 Sep;25(9):509-15.

PMID:
19746240
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Renal dysfunction increases the risk of saphenous vein graft occlusion: results from the Post-CABG trial.

Wellenius GA, Mukamal KJ, Winkelmayer WC, Mittleman MA.

Atherosclerosis. 2007 Aug;193(2):414-20. Epub 2006 Aug 14.

PMID:
16905139
[PubMed - indexed for MEDLINE]
7.

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

Post Coronary Artery Bypass Graft Trial Investigators.

N Engl J Med. 1997 Jan 16;336(3):153-62. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859.

PMID:
8992351
[PubMed - indexed for MEDLINE]
Free Article
8.

The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy.

Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ.

J Am Coll Cardiol. 2008 Aug 19;52(8):620-5. doi: 10.1016/j.jacc.2008.05.021.

PMID:
18702964
[PubMed - indexed for MEDLINE]
Free Article
9.

Effect of the dynamics of depression symptoms on outcomes after coronary artery bypass grafting.

Foss-Nieradko B, Stepnowska M, Piotrowicz R.

Kardiol Pol. 2012;70(6):591-7. English, Polish.

PMID:
22718378
[PubMed - indexed for MEDLINE]
10.

Hematologic parameters, atherosclerotic progression, and prognosis in patients with previous coronary artery bypass grafting (from the Post CABG Trial).

Mukamal KJ, Wellenius GA, Mittleman MA.

Am J Cardiol. 2009 Feb 1;103(3):328-32. doi: 10.1016/j.amjcard.2008.09.080. Epub 2008 Nov 19.

PMID:
19166684
[PubMed - indexed for MEDLINE]
11.

Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.

Hunninghake DB.

Am J Med. 1998 Feb 23;104(2A):9S-13S.

PMID:
9550501
[PubMed - indexed for MEDLINE]
12.

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y.

Circulation. 1999 Jun 29;99(25):3241-7.

PMID:
10385497
[PubMed - indexed for MEDLINE]
Free Article
13.

Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.

Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, Sachdev V, Knatterud G, Braunwald E.

Am J Cardiol. 2008 Oct 15;102(8):1023-7. doi: 10.1016/j.amjcard.2008.05.053. Epub 2008 Aug 9.

PMID:
18929703
[PubMed - indexed for MEDLINE]
14.

Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery.

Chen L, Théroux P, Lespérance J, Shabani F, Thibault B, De Guise P.

J Am Coll Cardiol. 1996 Nov 15;28(6):1493-9.

PMID:
8917263
[PubMed - indexed for MEDLINE]
Free Article
15.

Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.

Kang S, Liu Y, Liu XB.

Clin Ther. 2013 Aug;35(8):1125-36. doi: 10.1016/j.clinthera.2013.06.006. Epub 2013 Aug 7. Review.

PMID:
23932462
[PubMed - indexed for MEDLINE]
Free Article
16.

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.

Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y.

Am Heart J. 2003 Feb;145(2):262-9.

PMID:
12595843
[PubMed - indexed for MEDLINE]
17.

Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts.

Mukamal KJ, Girotra S, Mittleman MA.

Am Heart J. 2006 Feb;151(2):368-72.

PMID:
16442902
[PubMed - indexed for MEDLINE]
18.

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C.

Circulation. 2000 Jul 11;102(2):157-65.

PMID:
10889125
[PubMed - indexed for MEDLINE]
Free Article
19.

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.

Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL.

Atherosclerosis. 1999 Oct;146(2):369-79.

PMID:
10532693
[PubMed - indexed for MEDLINE]
20.

Self-reported memory symptoms with coronary artery disease: a prospective study of CABG patients and nonsurgical controls.

Selnes OA, Grega MA, Borowicz LM Jr, Barry S, Zeger S, McKhann GM.

Cogn Behav Neurol. 2004 Sep;17(3):148-56.

PMID:
15536302
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk